Synovial sarcoma is an aggressive soft tissue tumor characterized by a specific chromosomal translocation between chromosome 18 and X. This translocation can generate a fusion transcript encoding SYT-SSX1, a transforming oncoprotein. We present evidence that SYT-SSX1 induces insulin-like growth factor II expression in fibroblast cells. SYT-SSX2, a fusion also frequently found in synovial sarcoma, is necessary for maintaining Igf2 expression in the synovial sarcoma cell line, and the increased IGF2 synthesis protects cells from anoikis and is required for tumor formation in vivo. We also found a loss of imprinting (LOI) for Igf2 in a limited number of primary synovial sarcomas despite demethylation of CpG dinucleotides critical for maintaining imprinting. These findings suggest that inhibition of the IGF2/IGF1-R signaling pathway may represent a significant therapeutic modality for treating synovial sarcoma.
Introduction
Chromosomal translocations represent one of the major genetic alterations seen in a variety of human tumors (Rabbitts, 1994) . They result in deregulated gene transcription, or in many cases, a fusion gene encoding a hybrid protein that exhibits novel functions. An example of the latter class is seen in the translocations found in the great majority of chronic myeloid leukemias (CML) that cause the formation of the fusion gene Bcr-Abl, which has been shown in animal models to be directly responsible for inducing this disease (Wong and Witte, 2001 ).
Synovial sarcoma is a soft tissue sarcoma accounting for about 10% of sarcomas (Ladanyi, 2001) . The tumor has been found throughout the body with a low 5-year survival rate due to tumor metastasis. In virtually all synovial sarcomas, a specific chromosomal translocation has been found between chromosome 18 and X. The gene synovial sarcoma translocated (SYT) on chromosome 18 is fused to the SSX genes on the X chromosome (Clark et al., 1994a) . Two of the SSX genes, SSX1 and 2 have been found to be the major partners for fusion to the SYT gene (Crew et al., 1995) . These translocations remove the last eight amino acids of SYT and fuse it to the C-terminal portion of the SSX to yield the SYT-SSX fusion protein.
The presence of SYT-SSX in synovial sarcomas suggests that the fusion protein likely plays a critical role in the formation of the tumor. This points to the need to elucidate the molecular mechanisms that are responsible for synovial sarcoma formation. Importantly, the STY-SSX1 gene has been found to be capable of transforming fibroblasts. Thus, ectopic expression of SYT-SSX1 in the 3Y1 rat fibroblast cell line caused cells to grow in an anchorage-independent fashion in soft agar and to form tumors in nude mice (Nagai et al., 2001) .
SYT is a nuclear protein possessing two distinct domains, a novel 54 amino acid N-terminal domain, called SNH, as well as a QPGY domain that is rich in glutamine, proline, glycine and tyrosine residues; these amino acids are typically found in protein regions responsible for transcriptional activation. While SYT does not appear to have a recognizable DNA-binding motif, it can regulate transcription when fused to the Gal4 DNA-binding domain (Brett et al., 1997; Thaete et al., 1999) . These analyses have revealed that the SNH motif inhibits transcriptional activation by the QPGY domain, while the latter indeed behaves as a transcriptional activator.
SYT has also been found to bind to the p300 transcriptional coactivator (Eid et al., 2000) . This interaction is detected in confluent cells arrested in G0/ G1 but not in sparsely growing cells or in cells during the S and G2 phases of the cell cycle. The SYT and p300 interaction promotes cell adhesion to fibronectin, while an SYT mutant, and possibly SYT-SSX, weakens such interaction (Eid et al., 2000) .
Both SYT and the SYT-SSX fusion protein can bind to SNF2a, a component of the SWI/SNF complex involved in chromatin remodeling (Thaete et al., 1999; Nagai et al., 2001) . Indeed, SYT was found to be a component of a SWI/SNF complex, having been copurified with the latter in an affinity purification scheme (Kato et al., 2002) . It is thus possible that SYT or SYT-SSX, by interacting with SNF2, can direct the chromatin-remodeling complex to a particular promoter, where this complex can activate transcription through localized modification of chromatin structures.
SSX proteins are a group of X-chromosome encoded homologous proteins expressed only in the testis (Tureci et al., 1998) . Sequence analysis indicates that N-terminal regions of SSX1 and SSX2 have similarity to a transcription repression domain, the Kru¨ppel-associated box (KRAB) (Lim et al., 1998) . Analyses conducted by fusing various SSX domains to the Gal4 DNA-binding domain have shown that the C-terminal region of the SSX protein is a more potent inhibitor for transcription on this synthetic promoter. Moreover, the C-terminal domain of SSX1 that is present in the SYT-SSX1 protein has been found to strongly interact with core histones and oligonucleosomes (Kato et al., 2002) , which is compatible with the notion that SSX regulates transcription through interaction with chromatin structural proteins. A structure-function study indicates that the oncogenic potential of the SYT-SSX1 fusion protein was correlated with and dependent upon its ability to bind to the SNF2a, the chromosome remodeling protein mentioned above (Nagai et al., 2001) .
The target genes that are differentially regulated by the SYT-SSX oncoprotein are likely to play key roles in the pathogenesis of synovial sarcomas. A recent microarray analysis of 14 synovial sarcomas, as compared to four malignant fibrous histiocytomas and one fibrosarcoma, suggested the existence of a distinct expression profile for synovial sarcoma, including high expression of ERB-B2, IGFBP2 and IGF2 (Allander et al., 2002) . Immunohistochemical analysis of protein expression in tissue microarrays confirmed that in a subset of tumors, there is a strong expression of ERB-B2 and IGFBP2. However, the functional significance of this gene expression in synovial sarcoma pathogenesis was not clear.
Insulin-like growth factors 1 and 2 (IGF-1 and -2), together with their receptors, six binding proteins (IGFBPs) and IGFBP proteases, play key roles in cell growth, differentiation and apoptosis (Schmid, 1995; O'Dell and Day, 1998) . IGFs are expressed ubiquitously and impact on cell proliferation through endocrine as well as paracrine and autocrine signaling channels. The IGFs interact with specific cell surface type I and II receptors, and can also interact with the insulin receptor. Activation of the IGF-1 receptor can lead both to the activation of the canonical MAP kinase cascade as well as activation of PI-3 kinase, which in turn leads to the activation of Akt/protein kinase B; the latter, once activated, can stimulate cell proliferation and protect the cell from apoptosis. IGF2 expression is controlled by genomic imprinting where the paternal allele is active in transcription while the maternal allele is silent due to a lack of methylation at the ICR (imprinting control region) (Giannoukakis et al., 1993; Ogawa et al., 1993; Ohlsson et al., 1993; Rainier et al., 1993) . An 11-zincfinger transcription factor CTCF has been linked with binding to that region and is shown to be critical for maintaining IGF2 imprinting (Hark et al., 2000; Holmgren et al., 2001) .
We report here that SYT-SSX expression is tightly correlated with upregulation of IGF2 in normal fibroblasts as well as in synovial sarcoma cells. The increased IGF2 is functionally significant to protect cells from apoptosis during anchorage-independent growth, and is required for tumor formation by SYT-SSX1 in immunocompromised mice. A loss of imprinting (LOI) of IGF was found in a cohort of synovial sarcomas with concomitant demethylation at the CpG islands essential for CTCF binding. These studies delineate a clear pathway for SYT-SSX1 to contribute to synovial sarcoma formation, and suggest that targeting the IGF2 signaling pathway might be an effective therapy for synovial sarcoma and possibly other tumors as well.
Results

Overexpression of IGF2 in cells expressing SYT-SSX1
To understand how SYT-SSX1 contributes to the pathogenesis of synovial sarcomas, we undertook to determine the identity of the target genes regulated by SYT-SSX. Although the exact cellular origin of synovial sarcoma is not known, mesenchymal cells can be transformed by SYT-SSX1 (Nagai et al., 2001) . Consequently, we inserted the gene for hTERT, human telomerase catalytic subunit, in MRC5 human primary lung fibroblasts in order to derive an immortalized version of this line. Thereafter, we generated three derivatives of this cell line by introducing into these cells either the pBabe puro vector, the vector encoding a Flag epitope-tagged SYT, or a Flag-tagged SYT-SSX1. In this instance, we used SYT rather than SSX as a control for SYT-SSX, because the fusion protein carries virtually the entire SYT protein except for its last 8 amino-acid residues, while it contains only a half of SSX protein.
Following selection in puromycin, stable polyclonal cell populations were grown and harvested in parallel. We monitored the gene expression changes that result from SYT and SYT-SSX1 protein expression using oligonucleotide microarrays. Gene expression profiles were obtained with Affymetrix HU6800 arrays. Of the approximately 6800 genes and ESTs on the array, the gene that was most highly upregulated in the presence of SYT-SSX1 was IGF2 (Figure 1a) , with several isoforms all being registered to be highly expressed by the gene chip.
We therefore focused on IGF-2 as a potentially important mediator of SYT-SSX1 oncogenic function. To do so, we constructed a panel of neonatal rat kidney (NRK) cells carrying either a puromycin-resistance expression vector, or vectors encoding SYT or SYT-SSX1 with a Flag epitope at their N-termini. NRK cells SYT-SSX1 oncoprotein induces IGF2 Y Sun et al have been used previously to characterize growth factorinduced cellular transformation (Assoian et al., 1984) . In particular, transforming growth factors a and b, or epidermal growth factor plus TGF-b, can cause these cells to grow in an anchorage-independent manner. As shown in Figure 1b , these derivative NRK cells indeed expressed the SYT or SYT-SSX1 protein as detected by the anti-Flag antibody. SYT-SSX1 expression led to elevated expression of the Igf2 transcript, as gauged by the semi-quantitative PCR assay (Figure 1c ). SYT expression, on the contrary, led to a decline of Igf2 expression unlike that in the MRC5 cells. It is possible that at a low expression level, the microarray measurement of gene expression is less quantitative than that by PCR with limited cycles of amplification.
Human synovial sarcomas with SYT-SSX1 expression have worse prognostic outcome for patients than those with SYT-SSX2 expression . We therefore wish to examine whether Igf2 expression could underline that diagnostic distinction. We collected 15 human synovial sarcoma samples, and found that only two have clear SYT-SSX2 expression while the majority have the SYT-SSX1 fusion gene (Figure 1d) . The semiquantitative PCR analysis indicated that there was no discernible difference in Igf2 expression between the two genotypes although the limited sample size precluded a rigorous analysis of this comparison. To circumvent this limitation, we also compared Igf2 expression in NRK cells with SYT-SSX1 or SYT-SSX2 expression. As shown in Figure 1e , there was no clear difference of Igf2 expression between cells expressing either SSX1 or SSX2 version of the fusion protein. These findings suggest that SYT-SSX1 and SYT-SSX2 are functionally similar in their ability to upregulate Igf2, consistent with the results of microarray analysis performed on 14 human synovial sarcoma samples (Allander et al., 2002) , and further support the notion that regulation of Igf2 by SYT-SSX in these cells represents a part of the . Upon puromycin selection, Igf2 was examined with PCR as in (c), while SYT-SSX1 and 2 expression were detected by anti-SYT antibody with beta-actin as a loading control. (f) The Igf2 gene is downregulated in the synovial sarcoma cell line Bax in response to SYT-SSX-specific antisense oligonucleotides. The synovial sarcoma cell line was transfected with antisense oligo specific to the fusion gene or with an oligo of a scrambled sequence. At 24 h after transfection, total RNA was extracted, and Igf2 was examined as in (c). AS: antisense; C: control oligo; Neg.: PCR without template.
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To test whether Igf2 overexpression in synovial sarcoma is induced and maintained by SYT-SSX, we introduced into a synovial sarcoma cell line an antisense oligo directed specifically against the SYT/SSX fusion junction. Another oligonucleotide with a scrambled sequence was used as a negative control. These oligonucleotides were designed with phosphothiorate bonds at three positions at the 5 0 and 3 0 ends to render the oligonucleotides resistant to nuclease activity while also minimizing their nonspecific protein-binding capacity. The synovial sarcoma cell line Bax carries an SYT-SSX2 fusion gene (Crew et al., 1995) , which as described earlier is essentially identical to SYT-SSX1 except for a difference of eight amino acids in the SSX portion of the protein. As shown in Figure 1f , in response to antisense oligo specific to the fusion gene, the abundance of Igf2 transcripts was downregulated while GAPDH transcripts did not change. This suggests that SYT-SSX2 is necessary for IGF2 overexpression in established synovial sarcoma cells, and thus establishes a causal relationship between expression of SYT-SSX2 and IGF2.
IGF2 protects cells from apoptosis
The molecular connection between SYT-SSX1 and overexpression of IGF2 suggested that SYT-SSX1 might contribute to the synovial sarcoma formation through upregulation of IGF2. As described earlier, IGF2 is a well-known mitogen as well as a survival factor and its overactivity has been implicated in several human tumors. To examine whether IGF2 acts as a mitogen or a survival factor in SYT-SSX1-mediated cell transformation, we undertook a series of experiments. Initially, we compared the anchorage-independent growth of NRK cells expressing SYT-SSX1, SYT or vector control. For this purpose, cells were placed into methylcellulose, which prevents cell adhesion to substratum while facilitating cell retrieval for downstream analysis. As shown in Figure 2a , there were more viable cells by the criterion of trypan blue exclusion at day 4 culture of the cells expressing SYT-SSX1 while there was no marked difference in total cell number among the three test populations. To examine whether the trypan blue exclusion is the result of active cellular apoptosis, we measured the percentage of TUNEL-positive cells in the three populations of NRK cells. Consistent with the data shown in Figure 2a , there was a substantial decrease of TUNEL-positive cells in the SYT-SSX1-expressing population at day 3 of the suspension growth (see Figure 2b ). This indicates that SYT-SSX1 expression can suppress anoikis. To directly test whether this activity of SYT-SSX1 may be mediated via overexpression of IGF2, we incubated the three cell populations in suspension in the presence of a neutralizing antibody 4 cells were seeded into 1.5% methylcellulose containing 10% calf serum for 3 days before they were processed for TUNEL reactions followed by FACS analysis. The cells treated without TDT (terminal deoxyribonucleotide transferase) were used as negative control to give 0.4% of TUNEL positivity. (c) NRK cells grown to confluence were trypsinized and seeded into 1.5% methylcellulose containing 5% IFS plus EGF and TGF-b with or without 8 mg IGF2 neutralizing antibody for 48 h were processed for TUNEL as in (b). The ratio of percentage of TUNEL positive cells after the antibody treatment versus nontreated counterpart was plotted. (d) Human synovial sarcoma cell lines Bax and HA 2243 were grown to confluence, trypsinized and seeded into 1.5% methylcellulose containing 10% IFS for 48 h with no treatment as control, 8 mg IGF2 antibody. Cells were processed for TUNEL reactions as in (b).
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Y Sun et al against IGF2 for 48 h and examined the rate of apoptosis under these conditions. While the IGF2 neutralizing antibody had no effect on cell numbers under these conditions (data not shown), SYT-SSX1 expressing cells showed a threefold increase of TUNELpositivity in the presence of the IGF2 antibody. In contrast, vector control exhibited only a 1.5-fold increase of TUNEL-positive cells, and SYT-expressing cells actually showed a decrease (Figure 2c ). This suggests that overexpression of IGF2 by SYT-SSX1 indeed contributes to STY-SSX1-mediated cell survival in suspension, a condition that closely correlates with tumor growth in vivo.
To examine whether IGF2 expression may also be relevant for human synovial sarcoma cell survival, we examined the anchorage-independent growth of two well-characterized human synovial sarcoma cell lines in the presence or absence of IGF2 neutralizing antibodies. These two cell lines, Bax and HA2243, carry a fusion protein of SYT-SSX2 (Crew et al., 1995) . As shown in Figure 2d , treatment of IGF2 antibody, but not a control antibody, induced a significant increase of apoptosis in human synovial sarcoma cells as gauged by the number of TUNEL-positive cells.
IGF2 is required for tumor formation by SYT-SSX1
SYT-SSX1 has been shown to transform the Rat1 3Y1 cells by causing them to grow in soft agar and form a tumor in nude mice (Nagai et al., 2001) . The data presented above suggest that IGF2 can protect cells from anoikis; however, whether this anti-apoptotic effect has any bearing on tumorigenesis is not clear. To determine whether this increased IGF2 is required for tumorigenesis in vivo, we turned to the cells that can be transformed by SYT-SSX1. Rat1 3Y1 cells such as NRK cells express more Igf2 from their P3 promoter with expression of SYT-SSX1 than those with vector or SYT. SYT-SSX1 expression in rat1 cells leads to a reduced apoptotic rate during anchorage-independent growth in methycellulose ( Figure 3A ). Using SYT-SSX1 expressing cells as a starting population, we generated three derivatives of Rat1 3Y1 cells with varying degrees of Igf2, using small interference RNA strategy. Initially, the siRNA for Igf2 construct together with a vector conferring puromycin resistance were transfected into these cells, and drug-resistant cells were expanded as polyclonal populations and tested for Igf2 transcript levels and proliferation. As shown in Figure 3B , expression of siRNA for rat Igf2 results in a reduction of Igf2 transcript level and a diminished rate of proliferation, suggesting that IGF2 contributes a growth-promoting activity in this cell line, presumably as an autocrine factor. It has been recently reported that siRNA expression sometimes leads to nonspecific gene expression regulation (Jackson et al., 2003) . In order to control the specificity for the reduction of Igf2 expression by the siRNA vector, we also generated a clone of Rat1 3Y1 cells from the one carrying siRNA-Igf2 expression with ectopic expression of moue Igf2. Mouse IGF2 is 96% identical to rat IGF2 in amino-acid sequence and thus is likely to be as active as rat IGF2 considering that human IGF2 is active in rat cells even with 85% identity (Liu et al., 1996) . This Igf2 gene has been engineered to be resistant to the siRNA through silent mutagenesis at the siRNA target region. As shown in Figure 3C , these clones indeed express differing levels of Igf2 gauged by the RT-PCR analysis. The apoptotic rate of these three cell populations was measured similarly during culture in methylcellulose. As shown in Figure 3B , it was clear that a decreased Igf2 expression led to an increase of TUNEL positive cells in anchorage-independent growth while re-expression of mouse Igf2 only resulted in a modest rescue of apoptosis under these conditions. It is possible that the mouse Igf2 gene with no 5 0 and a short 3 0 UTR region is not as potent as the endogenous rat Igf2 gene due to differences in processing, binding or signaling. Interestingly, a reduction of type I IGF receptor by siRNA ( Figure 3E ), a receptor capable of mediating IGF2 signaling, results in substantial increase in TUNELpositive cells in SYT-SSX1-expressing cells during growth in methylcellulose, suggesting that type I IGF receptor is a major component conferring protection against anoikis like in many other cases during cellular transformation (Baserga, 1994) .
To test whether increased Igf2 expression is required for tumor formation induced by SYT-SSX1, we determined the in vivo tumor formation using the three clones of cells described above. These cells were injected subcutaneously into immunocompromised mice, and tumor formation was followed with visual and histological inspections (data not shown). Consistent with previous reports, SYT-SSX1 expression causes Rat1 3Y1 cells to form tumors in nude nice in 4 weeks. Histological examination indicates that the tumor resembles the human synovial sarcoma cells with compact spindle cell morphology ( Figure 3E(a) ). The cells with reduced Igf2 expression through expression of small interference RNA did not form tumors in the same time, while the cells with re-expression of mouse Igf2 gene resistant to the RNA interference only has a hint of tumor formation. However, around week 5 and 6, it became evident that while cells with reduced Igf2 expression did not form a clearly visible tumor mass, the cells with re-expression of mouse Igf2 formed tumors almost the same size as those vector control cells 10-14 days earlier. Histological examination indicates that these tumors have similar morphology as the synovial sarcoma cells (Figure 3E(b) ). In addition, a semiquantitative RT-PCR analysis indicated that the tumors maintained the Igf2 level (lane 4 of Figure 3C ). It is consistent with the in vitro observation that the ectopic expression of mouse Igf2 is not capable of fully suppressing the apoptosis during growth without substratum; thus, it might require a longer period of time to accumulate a visible tumor mass in vivo. These data suggest that SYT-SSX1-induced tumor formation is tightly connected with increased IGF2 expression, and a lack of tumor formation with expression of siRNA for Igf2 is specifically due to the downregulation of IGF2 since re-expression of Igf2 restores the tumorigenesis caused by SYT-SSX1 expression. Further histological
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Y Sun et al analysis of these tumors as shown in Figure 3E (c-f) indicates that like human synovial sarcoma, the tumors from rat1 cells similarly are positive for epithelial markers such as EMA, cytokeratin and E-cadherin, as well as strongly positive for Vimentin, which is a marker for fibroblast cells. It is unclear whether the rat1 3Y1 cells are of the nature of stem cells, and can thus be dedifferentiated into a more primitive state and in turn can be differentiated into cells with epithelial characteristics, or are just the results of marker expression during tumor formation.
SYT-SSX has been shown to interact with chromatin remodeling protein hSNF2a as well as p300 through its N-terminal domain (Eid et al., 2000; Nagai et al., 2001) . Mutant SYT-SSX1 proteins lacking the N-terminal domain, as well as the QPGY regions, fail to induce tumor formation in vivo. We wish to test whether there is a correlation between this molecular interaction with the upregulation of Igf2. We generated polyclonal populations of NRK cells with stable expression of SYT-SSX1 mutants carrying deletion of the N-terminal or QPGY domain, known 
Y Sun et al to be deficient in transformation (Nagai et al., 2001) ; however, whether these mutants still possess the ability to induce Igf2 is not known. As shown in Figure 4b , it is clear that only the cells with expression of full-length SYT-SSX1 are capable of inducing Igf2 transcript in these cells while others fail to do so, even though there is measurable protein expression of the mutant proteins (Figure 4c ). We also examined the viability of these cells grown in an anchorage-independent manner. The viability of these cells grown in methylcellulose for 4 days was examined with trypan blue exclusion. As shown in Figure 4a , only cells with SYT-SSX1 expression exhibited a substantial increase in trypan-blue exclusion while all others displayed a comparable level of viability when measured by this method. These data strongly suggest a tight correlation between SYT-SSX1/ SNF2a interaction and SYT-SSX1's ability to induce overexpression of Igf2 as well as a consequent protection of cells from apoptosis during anchorage-independent growth.
An LOI of IGF2 expression in synovial sarcoma IGF2 overexpression has been linked with a variety of human cancers. Igf2 gene is one of the few clearly demonstrated imprinted genes in the human genome (Giannoukakis et al., 1993) . LOI of IGF2 has been shown to be responsible for higher IGF2 expression in Wilm's tumors and embryonal rhabdomyosarcomas (Ogawa et al., 1993; Rainier et al., 1993) . One potential mechanism for genomic imprinting involves differential methylation by recruiting proteins that specifically bind to methylated or unmethylated DNA (Bartolomei and Tilghman, 1997) . In the case of Igf2 imprinting, the paternal allele of Igf2 is methylated between the Igf2 and H19, a gene encoding a nontranslated RNA of unknown function that is located 3 0 of the Igf2 (Hark et al., 2000; Felsenfeld and Groudine, 2003) . This methylation prevents the binding of CTCF while the maternal allele is unmethylated to allow the binding of CTCF to act as an insulator between Igf2 and downstream enhancers, thereby suppressing Igf2 transcription. As a result of genomic imprinting, adult Igf2 expression is only about half of that during embryonic development.
To examine the imprinting status of the Igf2 locus in synovial sarcomas, we collected 15 primary synovial sarcoma samples and analysed their genotypes for informative Igf2 alleles. As shown in Figure 5a , there are three possible polymorphic Igf2 alleles so far in the human genome, and out of 15 synovial sarcoma samples, four tumors display allelic differences in exon 9 of the gene. We then analysed the mRNA expression of these four tumors, and examined the allelic status of the mRNAs. This analysis (Figure 5b ) demonstrated that in all four tumors, there are biallelic expression of the mRNA, while a normal control for tumor number 5 still maintains the imprinted status by expressing only one allele of the Igf2 gene. These results suggest that genomic imprinting of Igf2 in these informative synovial sarcomas has been lost, consistent with the increased expression of Igf2 transcript found in these tumors.
We wish to further examine whether the LOI in these tumors is correlated with a loss of differential methylation known to be responsible for maintaining imprinting. The sixth CTCF binding site situated 3 0 of Igf2 locus has been extensively examined and found to be tightly linked with the imprinting status of Igf2 expression (Frevel et al., 1999; Stadnick et al., 1999; Bell and Felsenfeld, 2000; Hark et al., 2000; Nakagawa et al., 2001; Takai et al., 2001) . Thus, we analysed the methylation status of the CTCF binding site in that region with bisulfite treatment (Frommer et al., 1992; Clark et al., 1994b) , which converts the nonmethylated cytosines into uracil to generate two different sequences based on the methylation status of the CpG islands. We amplified by PCR the region around the CTCF binding site on the bisulfite-treated genomic DNA from Figure 4 Mutant SYT-SSX fails to induce Igf2 expression and protect cells from anoikis. (a) Polyclonal population of NRK cells with stable integration of various constructs were grown to confluence, and starved for 4 days before they were trypsinized and seeded into 1.5% methylcellulose containing 20% calf serum supplemented with 2.5 ng/ml TGF-b and 10 ng/ml EGF for 4 days before they were retrieved. The total number of cells as well as trypan-blue cells were counted and the ratio of trypan blue cells over the total was plotted. (b) Igf2 expression was monitored through semi-quantitative PCR in the five cell populations of cells. Gapdh level was used to gauged the input RNA as performed in Figure 1 . Lane 6 is the control PCR without cDNA template. (c) SYT-SSX delN and delQPGY proteins were detected by anti-Flag antibody followed by immunoprecipitation from same amount of lysate. Lane 1, vector control; lane 2, SYT-SSX delN; lane 3, SYT-SSX delQPGY.
Y Sun et al the four informative tumor samples followed by molecular cloning. Fortunately, earlier sequencing analysis indicated that these tumors all carry a polymorphic single-nucleotide site in this particular stretch of DNA, thus making it possible to mark the parent of origin of the alleles (data not shown). We collected 2-3 clones of each allele from each tumor, and analysed the CTCF methylation status with two pairs of primers reflecting the methylation status of the CpG dinucleotides. To our surprise, all clones from these tumors displayed unmethylated version of the CpG sequences located in CTCF binding region, which has been shown to be critical for prevention of its binding. These results were further confirmed by direct sequencing of these clones (data not shown), while a normal control still maintains the differential methylation at that region (Figure 5d ). These results suggest that synovial sarcoma, like some colorectal carcinoma (Cui et al., 2002) , displays an LOI of Igf2 through hypomethylation at the differential methylation region that maintains the genomic imprinting. The precise mechanism for this type of LOI and the upregulation of IGF2 remains to be determined, as also a potential role of SYT-SSX1 in the IGF2 LOI.
Discussion
We present here experimental evidence that SYT-SSX1 oncoprotein leads to strong induction of Igf2 expression. Functionally, the increased IGF2 expression is critical both for tumor formation in vivo as well as for protection against anoikis in vitro, suggesting that suppression of anoikis could be a mechanism for SYT-SSX1-induced tumorigenesis. Furthermore, an LOI of Igf2 expression has been observed in synovial sarcoma with a hypomethylation of the CpG dinucleotides in the CTCF binding sites known to be critical for genomic imprinting. These data also suggest that our experimental system models a critical part of human synovial sarcoma formation and represents a significant advancement towards a mechanistic understanding of synovial sarcoma genesis. Our notion that IGF2 overexpression is important for synovial sarcoma formation is also supported by the microarray data from the synovial sarcoma samples. A microarray analysis of 14 synovial sarcoma samples suggests that Igf2 is highly expressed compared to other similar types of sarcomas (Allander et al., 2002) . Although its overexpression is not detected in a tissue SYT-SSX1 oncoprotein induces IGF2 Y Sun et al microarray of tumor samples, it is possible that IGF2, due to its small size, is difficult to detect by the in situ immunohistochemical methods that were used. It is worth noting that several microarray analyses regarding SYT-SSX and synovial sarcomas failed to detect the overexpression of Igf2. A gene profiling in the Rat1 3Y1 cells did not reveal the overexpression of Igf2 (Nagai et al., 2001) although it is clear from our experiments that increased Igf2 expression is necessary for these cells to form tumors in nude mice. Similarly, a microarray analysis of synovial sarcoma cells with or without the treatment of antisense oligonucleotides for SYT-SSX2 indicated that SYT-SSX2 might be responsible for the expression of DNA repair gene XRCC4 at the mRNA and protein level (Xie et al., 2003) . In that experimental setting, the antisense oligonucleotide may not be able to completely shut down the expression of the SYT-SSX2, thus suggesting that SYT-SSX2 could be a very potent oncoprotein capable of turning on Igf2 expression, possibly even at a low expression level. In addition, it is also possible that a particular cellular context or cell type is critical for a robust induction of Igf2 by SYT-SSX.
Igf2 overexpression has been linked with a variety of human cancers, including rhabodomyosarcoma, Wilms' tumor and neuroblastoma (Toretsky and Helman, 1996) , with an LOI being a major contributor for overexpression. In addition, increased IGF2 levels in the microenvironment of a tumor can also be achieved by a loss of heterozygosity with paternal chromosome duplication (Schroeder et al., 1987; Scrable et al., 1989; Pal et al., 1990) as well as excess transcriptional activation (Nielsen et al., 1994; Pedone et al., 1994) or a loss of transcriptional suppression (Drummond et al., 1992; Zhang et al., 1996) . We present clear evidence that there is an LOI in synovial sarcoma. However, this LOI is not linked with a hypermethylation of CTCF binding sites that was responsible for several cases of LOI in Wilm's tumor and rhabodomysarcomas. This finding adds to a growing list of LOI of Igf2, which is concurrent with hypomethylation at the intergenic region between Igf2 and H19 (Takai et al., 2001; Cui et al., 2002) . It remains open whether and how CTCF, as well as the enhancer 3 0 downstream of H19 known to upregulate Igf2 transcription, is involved in this kind of LOI. It can be speculated that the bound CTCF in these circumstances might be functionally inert upon binding to DNA. Regulation of CTCF activity has been found in B-cell development (Qi et al., 2003) as well as other developmental processes. It is possible that CTCF can be regulated not only at the level of its binding to DNA to serve as insulators, or in these circumstances at the level after binding to DNA. The precise mechanism for upregulation of Igf2 by SYT-SSX1 is yet to be determined.
Cells deficient in IGF-1R have been found to be unable to support transformation by different tumorigenic agents (viral, chemical and genetic) (Baserga, 1994) . Indeed, rat1 cells transformed by SYT-SSX1 exhibited enhanced anoikis when IGF1R is decreased by siRNA ( Figure 3D ). This requirement of IGF-1R signaling most likely derives from its ability to negate the strong susceptibility of transformed cells to apoptosis. Since IGF-1R is the major signaling receptor for IGF2, this is consistent with our results that SYT-SSX1 protects cells from apoptosis during anchorage-independent growth while IGF2 does not impact much on cellular proliferation on substratum. Similarly, reduced Igf2 expression in cells expressing SYT-SSX1 abrogates the tumor-forming ability of SYT-SSX1 in immunocompromised mice while there is only minor difference in growth on tissue culture dishes between cells with or without reduced Igf2 expression. Interestingly, an earlier study examining the IGF1R status in a collection of synovial sarcomas suggested that higher IGF1R expression is correlated with increased lung metastasis, and thus aggressiveness of the tumor (Xie et al., 1999) . It is very likely that increased IGF2 autocrine secretion in synovial sarcoma upon binding to the increased IGF1R will yield amplification of signaling at the membrane and result in more robust downstream effects to promote tumorigenesis and metastasis.
Increased expression level of IGF2 and/or type I IGF receptor has been associated with most human cancers. Targeting the signal transduction pathway of the IGF system thus will be an effective way to control or cure cancer with minor side effects considering that mice with nullizygous IGF2 live reasonably normally (DeChiara et al., 1990 (DeChiara et al., , 1991 . A variety of approaches have been attempted to inhibit the IGF-1R with varying degrees of success in preclinical settings. More recently, two new small molecule inhibitors of IGF-1R have been identified, and demonstrated a specificity and potency towards the IGF-1R receptor (Garcia-Echeverria et al., 2004; Mitsiades et al., 2004) . These two molecules have been further shown to be effective in reducing tumor formation or tumor burden with consequent extension of animal life. The two novel molecular agents likely will expand the list of successful biological or pharmaceuticals in inhibiting the receptor tyrosine kinase, like Herceptin and Gleevac, as effective therapies for cancer treatment. In this regard, based on our results, the anti-IGF-1R agents might prove efficacious for treatment of human synovial sarcoma.
Materials and methods
Culture of mammalian cells MRC5 and its immortalized derivatives, NRK, rat1 3Y1 were cultured in Dulbecco's modified Eagle's medium (Mediatech), supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, penicillin and streptomycin at 371C with 5% CO 2 . For anchorage-independent growth, 1.5-2% methylcellulose were prepared briefly as follows: methylcellulose (Sigma, M-0512) was autoclaved followed by dissolving in DMEM with stirring overnight at 41C. The clear viscous solution was centrifuged at 6000 r.p.m. in a swing bucket rotor for 45 min to remove the debris and the clear viscous material was mixed with an appropriate amount of serum for later use.
Generation of stable cell lines
Immortalized MRC5 cells were generated by infection with amphotropic pBabe-Hygromycin virus encoding human telomerase catalytic subunit (Hahn et al., 1999) . Polyclonal hygromycin-resistant cell populations were selected and maintained. To generate cells (MRC5/Tert, NRK) with expression of SYT and SYT-SSX protein, amphotropic (MRC5) or ecotropic (NRK) virus encoding Flag-tagged SYT and SYT-SSX were added to the culture followed by puromycin selection. Rat1 3Y1 cells with SYT, SYT-SSX1 or control vector have been described (Nagai et al., 2001) . To generate cells with reduced Igf2 through siRNA expression, SYT-SSX1-expressing cells were transfected with pbsk-U6 construct together with vector conferring puromycin resistance at a ratio of 10:1, and stable clones selected and verified through RT-PCR analysis of the Igf2 transcript level. These cell lines were again transfected with pcDNA3-mIgf2 (Invitrogen) together with vector conferring hygromycin resistance and selected in the presence of 150 mg/ml of hygromycin.
Nucleic acids
Antisense phosphothioate oligonucleotide was made commercially with the following sequence: T*C*T*TGGGCATGAT CTGGTCATA*T*C*C, a control with scrambled sequence: T*C*G*GGTTCATGTGCATGTCACA*T*T*C. The asterisk denotes the phosphothioate linkage. For siRNA construct for Igf2 gene, an U6-promoter-based plasmid (Miyagishi and Taira, 2002) is used according to the published protocol with the following sequence: 5 0 GACGCCTGCGCAGAGGCCT3 0 . The CMV-driven mouse Igf2 gene resistant to the siRNA was constructed by PCR to replace the sequence corresponding to the siRNA target with the sequence of GGAAGAT-TAAGGCGCGGA. The cDNA was cleaved and cloned at KpnI and XhoI sites present at the sequence, thus corresponding to seven nucleotides upstream of ATG starting codon and about 448 nucleotides 3 0 untranslated region. The expression of IGF2 was confirmed by in vitro translation (data not shown). cDNAs for tagged SYT and SYT-SSX were generated by PCR from those two genes in pbsk and PCRII and cloned into pBabe puro vector in frame with an N-terminal Flagepitope. Deletion constructs for SYT-SSX were essentially identical as previously described (Nagai et al., 2001 0 . RNA was isolated by using Qiagen RNaeasy kit, and cDNA was generated using SuperscriptII reverse transcriptase (Invitrogen).
Tumor genotyping and methylation Primary synovial sarcoma samples were obtained from CHTN (Collective Human Tissue Network) with institutional approval for handling human samples. Genomic DNA was isolated with a kit from Fermentas. To facilitate recordkeeping, an oligonucleotide is numbered and displayed graphically in Figure 5 , and all subsequent discussions will reference that number only (underlined nucleotide indicates the C to T transversion upon bisulfite treatment): 659/ CTCATACTTTATGCATCCCCGCAGCTAC; 660/CTGTG TGCTGTGTGTGCTGTCCGTT; 906/TGTTGAAGGTTG GGGAGATGGGA; 907/CCCAAACCATAACACTAAAAC CCTC; 917/GGAGATGGGAGGAGATATTAG; 918/CTTA AATCCCAAACCATAACACT; 919/CCTACACTACCGCC GCGCG; 920/CCTACACTACCACCACACA; 923/AAATC TAATACGACTCCT; 924/AAATCTAATACGACTCCC. Genotyping of the Igf2 alleles was performed with the oligonucleotide pair of 659/660. PCR products were separated on polyacrylamide gel and visualized through silver staining. RNA isolation and reverse transcription was the same as described above except for an additional DNase treatment to eliminate genomic DNA contamination during RNA isolation. Methylation status of the intergenic region between IGF2 and H19 was examined using bisulfite treatment followed by sequential nested PCR amplification. First round PCR was performed with the primer pair 906/907 with subsequent PCR using the 917/918 pair. These primers reflect the C to T transversion generated by bisulfite treatment. The amplified DNA was cloned in pBluecript vector, and genotyped (data not shown) with the primer pair 917/923 for A allele and 917/ 924 pair for G allele. Two or three clones from each genotype were then used as substrate for PCR amplification with the pair of 919/917 to detect methylated cytosine and the 920/917 pair to detect C to T transversion in the CTCF binding site.
Immunological reagents and procedures
Anti-IGF2 neutralizing antibody was from Upstate Biotechnology (clone S1F2) with a final concentration of 10 mg/ml. Anti-SYT antibody was from Santa Cruz. For immunoprecipitation and immunobloting, NRK cells expressing SYT, SYT-SSX and vector control were collected by trypsin and lysed in lysis buffer (20 mM KCl, 150 mM NaCl, 1% IGEPAL, 50 mM TrisHCl (pH 7.5), 50 mM NaF, 50 mM b-glycerolphosphate, 1 mM EGTA, 1 mM DTT and 1 Â protease inhibitor cocktail (Roche) and 10% glycerol). Immunoprecipitations were performed with anti-FlagM2 mouse monoclonal antibody (Sigma A1205) and protein G-sepharose (Pharmacia). Beads were washed three times in lysis buffer and immunoprecipitated proteins were detected by Western blotting with anti-Flag epitope mouse monoclonal antibody and subsequently with horseradish peroxidase-conjugated rabbit antimouse IgG (Biorad). Immunoreactive proteins were visualized by enhanced chemiluminescence (SuperSignal West Dura, Pierce Biotechnology).
TUNEL assay
Cells in methylcellulose were isolated through two washes in a large volume of 1XPBS À , and processed for TUNEL assay following the protocol for In Situ Cell Death Detection Kit (Roche) with minor modifications. Briefly, cells were fixed in 4% paraformaldehyde in PBS À for 60 0 at room temperature, then permeabilized through incubation in 0.1% Triton X-100 in 0.1% sodium citrate for 2 0 on ice. Cells were then washed twice in PBS À , and counted to input an equal number of cells (usually between 10 Â 10 4 to 50 Â 10 4 depending on the number of cells available). The cells were incubated in labeling buffer at 371C for 1 h (labeling buffer: 6 mM FITC-dUTP (Amersham), 60 mM dATP, 1 mM CoCl 2 , 1XTdT buffer with 18 U of terminal deoxynucleotide transferase (New England Biolab)). The negative control is without the enzyme. The cells were then washed twice in PBS À and subject to FACS analysis.
